First Generic Version of Twice-Yearly HIV Prevention Shot Clears FDA Review

The first generic version of lenacapavir, the twice-yearly injection that prevents HIV, has cleared the US Food and Drug Administration, announced on 2 November 2026. The maker is India's Dr. Reddy's Laboratories, and the price it is aiming for is a tiny fraction of the brand-name cost.

It is a tentative approval, the status the FDA gives generics while the originator's patents are still in force. That means the product cannot be sold in the United States, but it does open the door for its purchase by programs serving low- and middle-income countries.

What it means

Gilead Sciences' branded version, Yeztugo, carries a US list price of about $28,218 a year. The generic is projected to cost about $40 per person per year, under a price agreed with Unitaid, the Clinton Health Access Initiative (CHAI) and Wits RHI in 2025.

• Reach: 120 high-incidence, lower-resource countries covered by Gilead's voluntary licensing program
• Dosing: two injections a year
• Timing: about 16 months after the originator's prevention approval
• Supply: first deliveries are expected by the end of 2026, with Zambia likely among the first countries

Six manufacturers hold licenses to make generic lenacapavir. Dr. Reddy's is the first to win this FDA step.

"This should be the new standard for global health," said CHAI chief executive Neil Buddy Shah.

Honest context

A low price does not deliver itself. Saiqa Mullick of Wits RHI has stressed that affordable medicine alone is not enough, because countries also need health systems ready to deliver it. Injection-site reactions were common in the clinical trials of the originator, though mostly mild, and funding cuts have already shrunk the number of people receiving HIV prevention. The delivery dates are projections, and each country may also need its own approvals.

Still, a prevention tool that needs only two visits a year, priced within reach of national health programs, is a significant step.